• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多顺反子载体编码优化的安全开关用于 T 细胞受体修饰的 T 细胞过继治疗。

Multi-cistronic vector encoding optimized safety switch for adoptive therapy with T-cell receptor-modified T cells.

机构信息

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.

出版信息

Gene Ther. 2013 Aug;20(8):861-7. doi: 10.1038/gt.2013.4. Epub 2013 Jan 31.

DOI:10.1038/gt.2013.4
PMID:23364317
Abstract

T-cell receptor (TCR) gene transfer is an attractive strategy to equip T cells with defined antigen-specific TCRs using short-term in vitro procedures to target both hematological malignancies and solid tumors. TCR gene transfer poses different safety issues that might warrant the inclusion of a suicide gene. High affinity TCRs may result in on-target toxicity, and off-target reactivity directed against healthy tissue can be observed due to mixed TCR dimers. Inclusion of a suicide gene as a safety switch may abrogate these unwanted toxicities. Human CD20 has been proposed as a nonimmunogenic suicide gene targeted by widely used clinical-grade anti-CD20 antibodies that can additionally function as a selection marker. However, transduction of T cells with a multi-cistronic vector encoding both TCR and CD20 resulted in poor coexpression. In this study, we demonstrated that codon optimization of TCR and CD20 resulted in profound coexpression of both the preferentially expressed antigen in melanoma (PRAME)-TCR and CD20, allowing selective as well as efficient elimination of these engineered T cells in vitro. These results demonstrate the great potential of codon optimized CD20 to be broadly used in clinical trials as a safety switch.

摘要

T 细胞受体(TCR)基因转移是一种有吸引力的策略,可使用短期体外程序为 T 细胞配备定义明确的抗原特异性 TCR,以靶向血液系统恶性肿瘤和实体瘤。TCR 基因转移带来了不同的安全问题,这可能需要包含自杀基因。高亲和力的 TCR 可能导致靶毒性,并且由于混合 TCR 二聚体,可能会观察到针对健康组织的脱靶反应。包含自杀基因作为安全开关可能会消除这些不必要的毒性。人类 CD20 已被提议作为一种自杀基因,其靶标是广泛使用的临床级抗 CD20 抗体,该抗体还可以作为选择标记。然而,用编码 TCR 和 CD20 的多顺反子载体转导 T 细胞导致两者的共表达很差。在这项研究中,我们证明了 TCR 和 CD20 的密码子优化导致黑色素瘤中优先表达的抗原(PRAME)-TCR 和 CD20 的共表达显著增加,从而允许体外选择性和高效地消除这些工程化 T 细胞。这些结果表明,密码子优化的 CD20 具有很大的潜力,可以作为安全开关广泛用于临床试验。

相似文献

1
Multi-cistronic vector encoding optimized safety switch for adoptive therapy with T-cell receptor-modified T cells.多顺反子载体编码优化的安全开关用于 T 细胞受体修饰的 T 细胞过继治疗。
Gene Ther. 2013 Aug;20(8):861-7. doi: 10.1038/gt.2013.4. Epub 2013 Jan 31.
2
The CD20/alphaCD20 'suicide' system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells.CD20/αCD20“自杀”系统:具有改善的安全性和表达谱以及高效消除CD20转基因T细胞的新型载体。
Gene Ther. 2006 May;13(9):789-97. doi: 10.1038/sj.gt.3302705.
3
Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.通过逆转录病毒介导的单一T细胞受体转移同时产生CD8 +和CD4 +黑色素瘤反应性T细胞。
Cancer Res. 2005 Feb 15;65(4):1570-6. doi: 10.1158/0008-5472.CAN-04-2076.
4
Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.针对对CD20靶向抗体不敏感的CD20低表达B细胞恶性肿瘤进行TCR基因治疗的CD20特异性TCR的产生。
Oncotarget. 2016 Nov 22;7(47):77021-77037. doi: 10.18632/oncotarget.12778.
5
Elongation factor 1 (EF1alpha) promoter in a lentiviral backbone improves expression of the CD20 suicide gene in primary T lymphocytes allowing efficient rituximab-mediated lysis.慢病毒载体骨架中的延伸因子1(EF1α)启动子可提高原发性T淋巴细胞中CD20自杀基因的表达,从而实现利妥昔单抗介导的有效裂解。
Haematologica. 2004 Jan;89(1):86-95.
6
T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR.T 细胞受体 (TCR) 基因转移与慢病毒载体允许在不预先刺激内源性 TCR 的情况下,在幼稚和记忆 T 细胞中有效地重新定向肿瘤特异性。
Hum Gene Ther. 2009 Dec;20(12):1576-88. doi: 10.1089/hum.2009.117.
7
Genetically modulating T-cell function to target cancer.基因修饰 T 细胞功能以靶向癌症。
Semin Cancer Biol. 2012 Feb;22(1):14-22. doi: 10.1016/j.semcancer.2011.12.006. Epub 2011 Dec 24.
8
T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.在携带人类黑色素瘤的免疫缺陷小鼠中进行 T 细胞受体基因治疗:人类 T 细胞而非小鼠 T 细胞重现临床研究结果。
Hum Gene Ther. 2012 Feb;23(2):187-201. doi: 10.1089/hum.2010.126. Epub 2011 Dec 2.
9
Suicide genes as safety switches in T lymphocytes.自杀基因作为T淋巴细胞中的安全开关。
Cytotherapy. 2003;5(3):227-30. doi: 10.1080/14653240310001497.
10
Rapid re-expression of retrovirally introduced versus endogenous TCRs in engineered T cells after antigen-specific stimulation.在抗原特异性刺激后,工程化 T 细胞中逆转录病毒引入的与内源性 TCR 快速重新表达。
J Immunother. 2011 Mar;34(2):165-74. doi: 10.1097/CJI.0b013e318206a10c.

引用本文的文献

1
Molecular Insights and Emerging Strategies for Treatment of Metastatic Uveal Melanoma.转移性葡萄膜黑色素瘤治疗的分子见解与新兴策略
Cancers (Basel). 2020 Sep 25;12(10):2761. doi: 10.3390/cancers12102761.
2
Overhauling CAR T Cells to Improve Efficacy, Safety and Cost.改进嵌合抗原受体T细胞以提高疗效、安全性和降低成本。
Cancers (Basel). 2020 Aug 21;12(9):2360. doi: 10.3390/cancers12092360.
3
Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma.替苯妥昔单抗:用于治疗转移性葡萄膜黑色素瘤的T细胞重定向疗法
Cancers (Basel). 2019 Jul 11;11(7):971. doi: 10.3390/cancers11070971.
4
Improving the safety of cell therapy with the TK-suicide gene.利用胸苷激酶自杀基因提高细胞治疗的安全性。
Front Pharmacol. 2015 May 5;6:95. doi: 10.3389/fphar.2015.00095. eCollection 2015.
5
Genetically modified T cells for the treatment of malignant disease.用于治疗恶性疾病的基因改造T细胞。
Transfus Med Hemother. 2013 Dec;40(6):388-402. doi: 10.1159/000357163. Epub 2013 Nov 29.